NovaVive Signs a Co-Operation Agreement with Hoken Biotechnology to Register and Market Amplimuneā„¢ in Asia

NovaVive Inc.

NovaVive is a private Canadian immunobiology company founded in July, 2014. The Company acquired an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with regulator-approved products for cattle, horses and dogs. These products are currently sold to veterinarians in the U.S.A., Canada, Australia and New Zealand. The Company's head office is located in Napanee, Ontario, Canada.

Sign up to stay up-to-date with NovaVive news.

Recent News

MCWF (Amplimune) Significantly Improves Fertility and Decreases Clinical Mastitis and Metritis in Organic-Certified Dairy Herd

In a newly published study, the incidence rates of both clinical mastitis and metritis before 28 days in milk were lower, and pregnancy rates (3 time points) were higher in Amplimune-treated cows vs. placebo-treated controls.

learn more

AmplimuneĀ® Now Available in New Zealand

NovaVive's immunotherapy for calf scours - AmplimuneĀ® - is now available in the New Zealand market. The product was approved for sale by Agricultural Compounds and Veterinary Medicines (ACVM) last September.

learn more

MCWF Greatly Improves Pregnancy Success in Heifer Embryo Transfer Recipients

An abstract being presented at the 2021 IETS Virtual Conference summarizes data from a study showing 45% of Amplimune-treated embryo transfer recipient heifers achieved pregnancy at Day 60 vs. 28% of untreated controls.

learn more

Follow NovaVive on Social Media.